Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma

Background Hepatocellular carcinoma (HCC) is a major health problem worldwide. However, the popular tumor marker, AFP, lacks sensitivity although its specificity is high. Tissue biopsy is an invasive operation and may increase the risk of needle-track metastases. Heat shock protein 90 (HSP90) is a potential biomarker for tumor diagnosis and prognosis. This study aims to determine whether levels of plasma HSP90 alpha in HCC patients can be used as a cost-effective and simple test for the initial diagnosis of the disease. Methods Plasma samples were collected from 659 HCC patients, 114 secondary hepatic carcinoma (SHC) patients, 28 hepatic hemangioma patients and 230 healthy donors. The levels of HSP90 alpha were measured by ELISA. Results The levels of plasma HSP90 alpha in HCC patients were significantly higher than in healthy donors and in patients with hepatic hemangioma or SHC (144.08 +/- 4.98, 46.81 +/- 1.11, 61.56 +/- 8.20 and 111.96 +/- 10.08 ng/mL, respectively; p < 0.05 in all cases). The levels were associated with age (p = 0.001), BCLC stage (p < 0.001), levels of AFP (p < 0.001), tumor size (p < 0.001), tumor number (p < 0.001), PVTT (p < 0.001), EHM (p < 0.001) and Child-Pugh stage in the HCC cohort. In addition, the levels of plasma HSP90 alpha showed an upward trend along with the progression of the BCLC stage. ROC curve analysis showed that compared to AFP (AUC 0.922, 95%CI 0.902-0.938) or HSP90 alpha (AUC 0.836, 95%CI 0.810-0.860), the combination of HSP90 alpha and AFP (AUC0.943, 95%CI 0.925-0.957) significantly improved the diagnostic efficiency for HCC patients. Conclusion The results suggest that plasma Hsp90 alpha levels can be used as an initial diagnosis for patients with HCC in both rural and cosmopolitan settings.